Lymphomun (FBTA05) / Trion Pharma, NeoPharm - LARVOL DELTA

STP-LYM-01: Study of the Trifunctional Antibody FBTA05 and Donor Lymphocyte Infusion in B-cell Lymphoma After Allogeneic Stem Cell Transplantation (clinicaltrials.gov) - P1/2 | N=0 | Withdrawn | Sponsor: Technical University of Munich | Terminated ➔ Withdrawn

Combination therapy • Trial withdrawal • Bone Marrow Transplantation • Chronic Lymphocytic Leukemia • Hematological Malignancies • Leukemia • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Transplantation • CD20

Immunotargeting and therapy of cancer by advanced multivalence antibody scaffolds. (PubMed, J Drug Target) - "Novel multivalent Ab scaffolds (e.g., MDX-447, MT110, CD20Bi, TF2, and FBTA05) and mimetic Abs (e.g., Adnectin, DARPins, Ecallantide) offer improved pharmacokinetic and pharmacodynamic properties. Here, we discuss the avidity and multivalency and provide comprehensive insights into advanced Ab scaffolds used for immunotargeting and therapy of cancer."

Journal • Oncology